Evidence map›Paper›PMID 42141129›Full record

ArticleCommunications biology2026

GlycoAvatars: bead-coated membrane models for studying the cancer-immune cells interactome.

Andreia Miranda, Marta Relvas-Santos, Camila Lourenço, Eduardo Ferreira, Diogo M Cunha, Carlos Palmeira, Lúcio Lara Santos, Pieta K Mattila, José Alexandre Ferreira

Abstract read
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Andreia MirandaExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.ORCID http://orcid.org/0000-0002-5441-4888
Marta Relvas-SantosExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
Camila LourençoExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
Eduardo FerreiraExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
Diogo M CunhaInstitute of Biomedicine, and MediCity Research Laboratories, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-2036-2212
Carlos PalmeiraExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
Lúcio Lara SantosExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal.
Pieta K MattilaInstitute of Biomedicine, and MediCity Research Laboratories, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0003-2805-0686
José Alexandre FerreiraExperimental Pathology and Therapeutics Group, Research Center of IPO-Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC Raquel Seruca), Porto, Portugal. jose.a.ferreira@ipoporto.min-saude.pt.ORCID http://orcid.org/0000-0002-0097-6148

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immature protein O-glycosylation, characterized by the Tn antigen expression rather than complex glycans, is prevalent in advanced solid tumors and promotes immune evasion. We developed GlycoAvatars, magnetic beads coated with plasma-membrane glycoproteins from glycoengineered cancer cells reflecting these alterations, to identify cancer-immune cell interactomes. We uncovered numerous membrane and intracellular proteins involved in glycan-mediated immune signaling, providing a novel high-throughput strategy for identifying potential relevant molecular nodes foreseeing therapeutic targets.

Indexed as

Membrane GlycoproteinsNeoplasmsAntigens, Tumor-Associated, CarbohydrateCell Line, TumorGlycosylationHumansAntigens, Tumor-Associated, CarbohydrateMembrane Glycoproteins

Identifiers

PMID42141129
PMCPMC13429652

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.